ArticleInflammation2025
Oral Administration of Piperine Ameliorates Experimental Autoimmune Uveitis.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the impact of piperine on experimental autoimmune uveitis (EAU). EAU was induced by immunization with interphotoreceptor retinoid-binding protein emulsified in complete Freund adjuvant. Starting from day 8 post-induction, Lewis rats were given piperine (0, 20, 40, and 80 mg/kg-P.O.) or prednisolone (10 mg/kg-P.O.) for 18 consecutive days. The 80 mg/kg dose of piperine demonstrated superior regression of clinical symptoms, increased nitric oxide levels, and enhanced IDO activity in eye homogenates compared to other doses. The 40 and 80 mg/kg doses of piperine were more effective in promoting weight gain in EAU rats than the 20 mg/kg dose. EAU rats treated with 80 mg/kg piperine showed more favorable mRNA expression of IL-10 and TGF-β in their eyes than other treatment groups. The interventions led to a significant decrease in mRNA ratios of T-bet/GATA-3, RORγt/T-bet, RORγt/Foxp3, and RORγt/GATA-3 in the eyes of EAU rats compared to untreated EAU rats. Specifically, EAU rats treated with 80 mg/kg piperine exhibited a greater reduction in the mRNA ratio of RORγt/Foxp3 expression compared to other treatment groups. Overall, oral administration of piperine may offer potential for clinical application in uveitis.
Indexed as
Identifiers
39196471What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.